Is bioXXmed AG halal to invest in?

According to Musaffa's Shariah screening methodology, bioXXmed AG (T5O.DE) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is bioXXmed AG a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes bioXXmed AG using these criteria to determine its compliance status.

Can Muslims buy shares of bioXXmed AG?

Muslim investors may consider investing in bioXXmed AG if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is bioXXmed AG classified as NOT HALAL?

Musaffa determines the Shariah status of bioXXmed AG by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for bioXXmed AG updated?

The Shariah compliance status of bioXXmed AG may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like bioXXmed AG become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of bioXXmed AG?

You can check the latest Shariah compliance status of bioXXmed AG on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

bioXXmed AG T5O.DE

€2.78 €0.03 (1.07%) 1D

Last Updated: Nov 22, 12:00 AM·XETRA

T5O.DE Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: July 24, 2025

Report Source: 2024 2nd Quarter Report

bioXXmed AG. Stock Analysis T5O.DE

Germany Health Care Nano Cap Report: Q2, 2024

bioXXmed AG is a biotechnology company, which engages in the research and development of therapies to treat cause of diseases. The company is headquartered in Darmstadt, Hessen and currently employs 1 full-time employees. The company went IPO on 2007-05-18. The firm holds interests in research and development (R&D) companies DermaTools Biotech GmbH, which is active in the field of dermatology and urology, and CytoPharma GmbH, which is engaged in product development for cardiovascular diseases, cancer and other indications. bioXXmed AG manages the patent portfolio and coordinates the licensing for its subsidiaries. The product pipeline of disease modifying therapies based on the mechanisms of cell growth and programmed cell death, comprising small molecules and biologics across a range of disease indications, includes DermaPro, the Company's lead product indicated for diabetic and venous foot ulcers in phase III of clinical trials, as well as Utisept, an urological medical device for flushing the bladder in urinary tract infections.

Key Statistics of bioXXmed AG (T5O.DE)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

€2.65€2.81

Today's Open

€2.81

Volume

682.00

P/E Ratio (TTM)

52 Week Range

€0.50€3.65

Market Cap

2.28M

Avg. Volume

174.06

Dividend Yield

Financial Metrics & Statements of bioXXmed AG (T5O.DE)

FAQ's for bioXXmed AG (T5O.DE)

According to Musaffa’s Shariah screening methodology, bioXXmed AG (T5O.DE) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.